Ved en kombineret analyse af patienter med moderat til svær RLS fra de fire 12- ugers undersøgelser var den tilnærmede behandlingsforskel for ændringen fra baseline i IRLS skalaens totale score uge 12 Last Observation Carried Forward (LOCF) Intention to Treat population - 4, 0 points (95% CI - 5, 6, - 2, 4, p < 0, 0001; baseline og uge 12 LOCF middel IRLS points: ropinirol 28, 4 og 13, 5; placebo 28, 2 og 17, 4).
In a combined analysis of moderate to severe Restless Legs Syndrome patients from the four 12-week studies, the adjusted treatment difference for the change from baseline in IRLS scale total score at week 12 Last Observation Carried Forward (LOCF) Intention To Treat population was -4.0 points (95% CI -5.6, - 2.4, p < 0.0001; baseline and week 12 LOCF mean IRLS points: ropinirole 28.4 and 13.5; placebo 28.2 and 17.4).